688 related articles for article (PubMed ID: 23154075)
1. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal.
Kachnic LA; Winter K; Myerson RJ; Goodyear MD; Willins J; Esthappan J; Haddock MG; Rotman M; Parikh PJ; Safran H; Willett CG
Int J Radiat Oncol Biol Phys; 2013 May; 86(1):27-33. PubMed ID: 23154075
[TBL] [Abstract][Full Text] [Related]
2. Predictors of Radiation Therapy-Related Gastrointestinal Toxicity From Anal Cancer Dose-Painted Intensity Modulated Radiation Therapy: Secondary Analysis of NRG Oncology RTOG 0529.
Olsen JR; Moughan J; Myerson R; Abitbol A; Doncals DE; Johnson D; Schefter TE; Chen Y; Fisher B; Michalski J; Narayan S; Chang A; Crane CH; Kachnic L
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):400-408. PubMed ID: 28463160
[TBL] [Abstract][Full Text] [Related]
3. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy.
Kachnic LA; Tsai HK; Coen JJ; Blaszkowsky LS; Hartshorn K; Kwak EL; Willins JD; Ryan DP; Hong TS
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):153-8. PubMed ID: 21095071
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Outcomes of NRG Oncology/RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Anal Canal Cancer.
Kachnic LA; Winter KA; Myerson RJ; Goodyear MD; Abitbol AA; Streeter OE; Augspurger ME; Schefter TE; Katz AW; Fisher BJ; Henke LE; Narayan S; Crane CH
Int J Radiat Oncol Biol Phys; 2022 Jan; 112(1):146-157. PubMed ID: 34400269
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer.
Leon O; Guren MG; Radu C; Gunnlaugsson A; Johnsson A
Eur J Cancer; 2015 Dec; 51(18):2740-6. PubMed ID: 26597443
[TBL] [Abstract][Full Text] [Related]
6. Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer.
Han K; Cummings BJ; Lindsay P; Skliarenko J; Craig T; Le LW; Brierley J; Wong R; Dinniwell R; Bayley AJ; Dawson LA; Ringash J; Krzyzanowska MK; Moore MJ; Chen EX; Easson AM; Kassam Z; Cho C; Kim J
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):587-94. PubMed ID: 25194664
[TBL] [Abstract][Full Text] [Related]
7. Intensity-modulated Radiotherapy for Anal Cancer: Dose-Volume Relationship of Acute Gastrointestinal Toxicity and Disease Outcomes.
Ng M; Ho H; Skelton J; Guerrieri M; Guiney M; Chao M; Blakey D; Macleod C; Amor H; Subramanian B; Melven L
Clin Oncol (R Coll Radiol); 2018 Oct; 30(10):634-641. PubMed ID: 30049649
[TBL] [Abstract][Full Text] [Related]
8. PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer.
Zimmermann M; Beer J; Bodis S; von Moos R; Vlachopoulou V; Zwahlen DR; Oehler C
Acta Oncol; 2017 Dec; 56(12):1734-1740. PubMed ID: 28557585
[TBL] [Abstract][Full Text] [Related]
9. Intensity-Modulated Radiotherapy (IMRT) vs Helical Tomotherapy (HT) in Concurrent Chemoradiotherapy (CRT) for Patients with Anal Canal Carcinoma (ACC): an analysis of dose distribution and toxicities.
Yeung R; McConnell Y; Warkentin H; Graham D; Warkentin B; Joseph K; Doll CM
Radiat Oncol; 2015 Apr; 10():92. PubMed ID: 25903798
[TBL] [Abstract][Full Text] [Related]
10. Intensity-modulated Radiation Therapy for Anal Cancer: Results From a Multi-Institutional Retrospective Cohort Study.
Call JA; Prendergast BM; Jensen LG; Ord CB; Goodman KA; Jacob R; Mell LK; Thomas CR; Jabbour SK; Miller RC
Am J Clin Oncol; 2016 Feb; 39(1):8-12. PubMed ID: 24401669
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of concurrent chemoradiotherapy with 5-fluorouracil and mitomycin-C for squamous cell carcinoma of the anal canal (the JROSG 10-2 trial).
Murofushi KN; Itasaka S; Shimokawa M; Murakami Y; Yamamoto T; Nishimura Y; Kudo S; Sakamoto T; Ariga T; Ogo E; Taguchi K; Jingu K; Ogawa K
J Radiat Res; 2023 Jan; 64(1):154-161. PubMed ID: 36280895
[TBL] [Abstract][Full Text] [Related]
12. Implementing Intensity-modulated Radiotherapy with Simultaneous Integrated Boost for Anal Cancer: 3 Year Outcomes at Two Sydney Institutions.
Yates A; Carroll S; Kneebone A; Tse R; Horvath L; Byrne C; Solomon M; Hruby G
Clin Oncol (R Coll Radiol); 2015 Dec; 27(12):700-7. PubMed ID: 26382849
[TBL] [Abstract][Full Text] [Related]
13. Impact of chemotherapy on normal tissue complication probability models of acute hematologic toxicity in patients receiving pelvic intensity modulated radiation therapy.
Bazan JG; Luxton G; Kozak MM; Anderson EM; Hancock SL; Kapp DS; Kidd EA; Koong AC; Chang DT
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):983-91. PubMed ID: 24161422
[TBL] [Abstract][Full Text] [Related]
14. Outcomes after intensity-modulated compared with 3-dimensional conformal radiotherapy with chemotherapy for squamous cell carcinoma of the anal canal.
Agarwal MS; Hitchcock KE; Morris CG; George TJ; Mendenhall WM; Zlotecki RA
Curr Oncol; 2019 Aug; 26(4):e515-e521. PubMed ID: 31548820
[TBL] [Abstract][Full Text] [Related]
15. [Management of locally advanced anal canal carcinoma with modulated arctherapy and concurrent chemotherapy].
Troussier I; Huguet F; Servagi-Vernat S; Benahim C; Khalifa J; Darmon I; Ortholan C; Krebs L; Dejean C; Fenoglietto P; Vieillot S; Bensadoun RJ; Thariat J
Cancer Radiother; 2015 Apr; 19(2):127-38. PubMed ID: 25770884
[TBL] [Abstract][Full Text] [Related]
16. Prospective phase II study of tomotherapy based chemoradiation treatment for locally advanced anal cancer.
Joseph K; Nijjar Y; Warkentin H; Schiller D; Tankel K; Usmani N; Severin D; Ghosh S; Syme A; Nijjar T; Mulder K; Doll C; Wong C; Field C
Radiother Oncol; 2015 Nov; 117(2):234-9. PubMed ID: 26306677
[TBL] [Abstract][Full Text] [Related]
17. Capecitabine With Mitomycin Reduces Acute Hematologic Toxicity and Treatment Delays in Patients Undergoing Definitive Chemoradiation Using Intensity Modulated Radiation Therapy for Anal Cancer.
Goodman KA; Julie D; Cercek A; Cambridge L; Woo KM; Zhang Z; Wu AJ; Reidy DL; Segal NH; Stadler ZK; Saltz LB
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1087-1095. PubMed ID: 28721892
[TBL] [Abstract][Full Text] [Related]
18. Haematotoxicity in IMRT/VMAT curatively treated anal cancer.
Lohynská R; Nýdlová A; Drbohlavová T; Mazaná E; Jirkovská M; Veselský T; Malinová B; Stankušová H
Klin Onkol; 2020; 33(4):288-294. PubMed ID: 32894958
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study.
Deenen MJ; Dewit L; Boot H; Beijnen JH; Schellens JH; Cats A
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):e201-7. PubMed ID: 23517808
[TBL] [Abstract][Full Text] [Related]
20. Pencil Beam Scanning Proton Beam Chemoradiation Therapy With 5-Fluorouracil and Mitomycin-C for Definitive Treatment of Carcinoma of the Anal Canal: A Multi-institutional Pilot Feasibility Study.
Wo JY; Plastaras JP; Metz JM; Jiang W; Yeap BY; Drapek LC; Adams J; Baglini C; Ryan DP; Murphy JE; Parikh AR; Allen JN; Clark JW; Blaszkowsky LS; DeLaney TF; Ben-Josef E; Hong TS
Int J Radiat Oncol Biol Phys; 2019 Sep; 105(1):90-95. PubMed ID: 31128146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
